 | |  | |  | |  | |  |
Amakem NV is developing kinase inhibitors with "localized drug action"
to treat chronic diseases, such as COPD and glaucoma, where
inflammation or auto-immunity play an important role. Amakem's
localized drug action platform is developed to avoid the systemic side
effects seen so often with kinase inhibitors.
Amakem is an early stage biopharmaceutical company based in
Belgium and located in the life sciences incubator “BioVille” on the
campus of the University of Hasselt. The company is focused on the
development of promising and innovative near clinical or clinical small
molecule drugs.
Early 2010 Amakem closed a seed financing round of 1.5M€ led by
LRM with further participation from Vinnof, Life Science Research
Partners and a contribution in kind of assets, intellectual property and
know-how of Devgen’s former pharma division.
Amakem was founded to continue the development of its unique, locally
acting kinase inhibitor concept (localized drug action) that the founders
embarked upon during their Devgen tenure.
to treat chronic diseases, such as COPD and glaucoma, where
inflammation or auto-immunity play an important role. Amakem's
localized drug action platform is developed to avoid the systemic side
effects seen so often with kinase inhibitors.
Amakem is an early stage biopharmaceutical company based in
Belgium and located in the life sciences incubator “BioVille” on the
campus of the University of Hasselt. The company is focused on the
development of promising and innovative near clinical or clinical small
molecule drugs.
Early 2010 Amakem closed a seed financing round of 1.5M€ led by
LRM with further participation from Vinnof, Life Science Research
Partners and a contribution in kind of assets, intellectual property and
know-how of Devgen’s former pharma division.
Amakem was founded to continue the development of its unique, locally
acting kinase inhibitor concept (localized drug action) that the founders
embarked upon during their Devgen tenure.
therapies for inflammatory diseases